BioCardia Announces Pause in Enrollment for Phase III CardiAMP Cell Therapy Heart Failure Trial SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease treatment, has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to temporarily pause new..
Teleflex Completes Enrollment in Percutaneous Coronary Intervention Study Teleflex Incorporated, a leading global provider of medical technologies, has announced the successful completion of patient enrollment in the RingerTM PTCA study. This groundbreaking study is one of two clinical trials that aim to evaluate the performance and effectiveness of the innovative RingerTM Perfusion Balloon Cath..
Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. The recommended phase 2 dose (RP2D) f..
Palisade Bio, a biopharmaceutical company focused on gastrointestinal complications, has announced the completion of patient enrollment in its LB1148 dose optimization study. The study aims to generate valuable data on pharmacokinetics and pharmacodynamics across multiple doses in healthy adult volunteers. This milestone brings Palisade Bio closer to obtaining Phase 2 topline data for the preven..
Ayala Pharmaceuticals, Inc. has successfully concluded an End-of-Phase 2 meeting with the FDA regarding AL102, a potential treatment for desmoid tumors. The company confirms agreement with the FDA on key elements of the Phase 3 segment of the ongoing RINGSIDE study, including the dosing regimen. Enrollment in Phase 3 is continuing as planned. Desmoid tumors are rare connective tissue tumors that..
